Literature DB >> 16972305

Gene profiling of cathepsin K deficiency in atherogenesis: profibrotic but lipogenic.

S P M Lutgens1, N Kisters, E Lutgens, R I M van Haaften, C T A Evelo, M P J de Winther, P Saftig, M J A P Daemen, S Heeneman, K B J M Cleutjens.   

Abstract

Recently, we showed that cathepsin K deficiency reduces atherosclerotic plaque progression, induces plaque fibrosis, but aggravates macrophage foam cell formation in the ApoE -/- mouse. To obtain more insight into the molecular mechanisms by which cathepsin K disruption evokes the observed phenotypic changes, we used microarray analysis for gene expression profiling of aortic arches of CatK -/-/ApoE -/- and ApoE -/- mice on a mouse oligo microarray. Out of 20 280 reporters, 444 were significantly differentially expressed (p-value of < 0.05, fold change of > or = 1.4 or < or = - 1.4, and intensity value of > 2.5 times background in at least one channel). Ingenuity Pathway Analysis and GenMAPP revealed upregulation of genes involved in lipid uptake, trafficking, and intracellular storage, including caveolin - 1, - 2, - 3 and CD36, and profibrotic genes involved in transforming growth factor beta (TGFbeta) signalling, including TGFbeta2, latent TGFbeta binding protein-1 (LTBP1), and secreted protein, acidic and rich in cysteine (SPARC), in CatK -/-/ApoE -/- mice. Differential gene expression was confirmed at the mRNA and protein levels. In vitro modified low density lipoprotein (LDL) uptake assays, using bone marrow derived macrophages preincubated with caveolae and scavenger receptor inhibitors, confirmed the importance of caveolins and CD36 in increasing modified LDL uptake in the absence of cathepsin K. In conclusion, we suggest that cathepsin K deficiency alters plaque phenotype not only by decreasing proteolytic activity, but also by stimulating TGFbeta signalling. Besides this profibrotic effect, cathepsin K deficiency has a lipogenic effect owing to increased lipid uptake mediated by CD36 and caveolins. Copyright 2006 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16972305     DOI: 10.1002/path.2054

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  6 in total

1.  Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.

Authors:  Sara Sjöberg; Guo-Ping Shi
Journal:  Clin Rev Bone Miner Metab       Date:  2011-06-18

2.  Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

Authors:  Izabela Podgorski
Journal:  Future Med Chem       Date:  2009-04       Impact factor: 3.808

3.  Lack of cathepsin activities alter or prevent the development of lung granulomas in a mouse model of sarcoidosis.

Authors:  Andriy O Samokhin; Jacques Yves Gauthier; M David Percival; Dieter Brömme
Journal:  Respir Res       Date:  2011-01-20

4.  Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation.

Authors:  Lili Pan; Yulin Li; Lixin Jia; Yanwen Qin; Guanming Qi; Jizhong Cheng; Yongfen Qi; Huihua Li; Jie Du
Journal:  PLoS One       Date:  2012-04-30       Impact factor: 3.240

5.  Cathepsin K Deficiency Prevents the Aggravated Vascular Remodeling Response to Flow Cessation in ApoE-/- Mice.

Authors:  Marjo M P C Donners; Lili Bai; Suzanne P M Lutgens; Erwin Wijnands; Jason Johnson; Leon J Schurgers; Cong-Lin Liu; Mat J A P Daemen; Kitty B J M Cleutjens; Guo-Ping Shi; Erik A L Biessen; Sylvia Heeneman
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

6.  Decreased cathepsin K levels in human atherosclerotic plaques are associated with plaque instability.

Authors:  Huiying Zhao; Xiujiao Qin; Shuai Wang; Xiwei Sun; Bin Dong
Journal:  Exp Ther Med       Date:  2017-08-16       Impact factor: 2.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.